NCT06745908 - ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

460

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

January 31, 2029

Conditions

NSCLC Stage IV

Interventions

DRUG

N-803

N-803 1.2 mg SC

DRUG

Tislelizumab

Tislelizumab 200 mg IV

DRUG

Docetaxel

Docetaxel 75 mg/m2 IV

Trial Locations (9)

30322

RECRUITING

Emory University - Winship Cancer Institute, Atlanta

33316

RECRUITING

The Oncology Institute of Hope and Innovation, Fort Lauderdale

37232

RECRUITING

Vanderbilt - Ingram Cancer Center, Nashville

45267

RECRUITING

University of Cincinnati Medical Center, Cincinnati

72762

RECRUITING

Highlands Oncology Group, Springdale

90245

RECRUITING

Chan Soon-Shiong Institute for Medicine, El Segundo

90720

RECRUITING

OPN Healthcare INC/ Cancer and Blood Specialty Clinic, Los Alamitos

91203

RECRUITING

OPN Healthcare INC, Glendale

33612-9497

RECRUITING

Moffit Cancer Center, Tampa